Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
August 09, 2022 16:01 ET
|
Journey Medical Corporation
Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of 2021 DFD-29 Phase 3 studies 45% enrolled to date; 9 additional sites underway in Europe open to enrollment ...
Journey Medical Corporation to Announce Second Quarter 2022 Financial Results on August 9, 2022
August 03, 2022 08:00 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity
May 24, 2022 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that focuses on the...
Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference
May 23, 2022 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 23, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
May 10, 2022 16:01 ET
|
Journey Medical Corporation
Generated record revenue of $23.3 million for the first quarter of 2022 First patient dosed in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea Company to hold...
Journey Medical Corporation to Announce First Quarter 2022 Financial Results on May 10, 2022
May 03, 2022 16:15 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 03, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
April 04, 2022 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., April 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
March 23, 2022 16:01 ET
|
Journey Medical Corporation
Generated record net product revenues of $63.1 million for the full year 2021 Completed initial public offering of common stock and raised $30.6 million in net proceeds Dosed first patient in Phase...
Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022
March 18, 2022 13:15 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., March 18, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea
March 17, 2022 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., March 17, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and...